Remdesivir: Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)-Analysis of Data from Daily Practice.
COVID-19
effectiveness
hospitalized patients
remdesivir
safety
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
03 Aug 2023
03 Aug 2023
Historique:
received:
04
07
2023
revised:
26
07
2023
accepted:
31
07
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Remdesivir was the first antiviral approved for treating COVID-19. We investigated its patterns of use, effectiveness and safety in clinical practice in Greece. This is a retrospective observational study of hospitalized adults who received remdesivir for COVID-19 in September 2020-February 2021. The main endpoints were the time to recovery (hospital discharge within 30 days from admission) and safety. The "early" (remdesivir initiation within 24 h since hospitalization) and "deferred" (remdesivir initiation later on) groups were compared. One thousand and four patients (60.6% male, mean age 61 years, 74.3% with severe disease, 70.9% with ≥1 comorbidities) were included, and 75.9% of them were on a 5-day regimen, and 86.8% were in the early group. Among those with a baseline mild/moderate disease, the median (95% CI) time to recovery was 8 (7-9) and 12 (11-14) days for the early and deferred groups, respectively (
Identifiants
pubmed: 37630558
pii: microorganisms11081998
doi: 10.3390/microorganisms11081998
pmc: PMC10459397
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Gilead Sciences, Inc.
ID : CO-GR-540-6245
Références
J Pharm Technol. 2022 Apr;38(2):75-87
pubmed: 35571345
Clin Infect Dis. 2021 Dec 6;73(11):e4166-e4174
pubmed: 32706859
N Engl J Med. 2020 Jun 18;382(25):e102
pubmed: 32356626
J Clin Med. 2021 Mar 15;10(6):
pubmed: 33804075
Ann Gastroenterol. 2022 May-Jun;35(3):290-296
pubmed: 35599935
Rev Esp Quimioter. 2021 Apr;34(2):136-140
pubmed: 33675220
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Am Fam Physician. 2019 Dec 1;100(11):687-694
pubmed: 31790176
J Pathol. 2020 Jul;251(3):228-248
pubmed: 32418199
Br J Clin Pharmacol. 2021 Mar;87(3):1432-1442
pubmed: 32964535
JAMA. 2020 Sep 15;324(11):1048-1057
pubmed: 32821939
Infect Dis (Lond). 2023 Oct;55(10):706-715
pubmed: 37427461
Cad Saude Publica. 2021 Nov 12;37(10):e00077721
pubmed: 34787281
Glob Epidemiol. 2022 Dec;4:100095
pubmed: 36447481
J Clin Med. 2022 May 31;11(11):
pubmed: 35683518
Clin Pharmacol Ther. 2021 Apr;109(4):1021-1024
pubmed: 33340409
BMC Med. 2023 Jan 4;21(1):1
pubmed: 36600273
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
J Family Med Prim Care. 2022 Jun;11(6):3133-3137
pubmed: 36119268
Clin Kidney J. 2021 Jan 24;14(Suppl 1):i30-i39
pubmed: 33796284
J Clin Med. 2022 Aug 29;11(17):
pubmed: 36078997
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
PLoS One. 2022 Mar 2;17(3):e0264547
pubmed: 35235580
Microorganisms. 2022 Sep 30;10(10):
pubmed: 36296225
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Front Pharmacol. 2022 Mar 25;13:692828
pubmed: 35401177
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Scand J Public Health. 2022 Aug;50(6):671-675
pubmed: 34903101
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Lancet. 2022 May 21;399(10339):1941-1953
pubmed: 35512728
J Glob Health. 2022 Aug 31;12:05031
pubmed: 36040909
Lancet Infect Dis. 2022 Feb;22(2):209-221
pubmed: 34534511
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812